TUESDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Athira Pharma, Inc. Class Action Lawsuit – ATHA
SAN DIEGO--(BUSINESS WIRE)--Aug 18, 2021--
Robbins Geller Rudman & Dowd LLP announces that the Athira Pharma class action lawsuit charges Athira Pharma, Inc. (NASDAQ: ATHA) and its CEO and directors, as well as the underwriters of Athira Pharma’s September 2020 initial public offering (“IPO”), with violations of the Securities Exchange Act of 1934 and/or Securities Act of 1933 and seeks to represent: (i) purchasers of Athira Pharma securities between September 18, 2020 and June 17, 2021, inclusive (the “Class Period”); and (ii) purchasers of Athira Pharma common stock traceable to Athira Pharma’s registration statement issued in connection with the IPO. The Athira Pharma class action lawsuit was initiated in the Western District of Washington and is captioned Wang v. Athira Pharma, Inc., No. 21-cv-00861. Two similar lawsuits subsequently filed in the Western District of Washington – Jawandha v. Athira Pharma, Inc., No. 21-cv-00862, and Slyne v. Athira Pharma, Inc., No. 21-cv-00864 – were consolidated with the Wang matter on August 9, 2021.
If you suffered substantial losses and wish to serve as lead plaintiff of the Athira Pharma class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at email@example.com. Lead plaintiff motions for the Athira Pharma class action lawsuit must be filed with the court no later than August 24, 2021.
CASE ALLEGATIONS: The Athira Pharma class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the research conducted by Athira Pharma’s President and Chief Executive Officer, defendant Leen Kawas, which formed the foundation for Athira Pharma’s product candidates and intellectual property, was tainted by Kawas’s scientific misconduct, including the manipulation of key data; and (ii) as a result, defendants’ positive statements about Athira Pharma’s business, operations, and prospects were materially misleading and omitted material facts necessary to make the statements made not misleading.
On June 17, 2021, Athira Pharma issued a press release announcing that Athira Pharma’s Board of Directors had placed Kawas on temporary leave pending a review of actions stemming from doctoral research Kawas conducted while at Washington State University. An article published in STAT News later that day revealed that the investigation of Kawas related to allegations that she altered images in four separate papers relating to her research on hepatocyte growth factor (HGF), a protein with the potential to treat Alzheimer’s disease and other neurological disorders. The article noted that although Athira Pharma “has since moved on to a different molecule than the one Kawas was working on, it still aims to target HGF. And so Kawas’s doctoral work laid the biological groundwork that Athira continues to use in their approach to treating Alzheimer’s.” On this news, Athira Pharma’s stock price fell by nearly 39%, damaging investors.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Athira Pharma securities during the Class Period and/or Athira Pharma common stock traceable to Athira Pharma’s registration statement issued in connection the IPO to seek appointment as lead plaintiff in the Athira Pharma class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Athira Pharma class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Athira Pharma class action lawsuit. An investor’s ability to share in any potential future recovery of the Athira Pharma class action lawsuit is not dependent upon serving as lead plaintiff.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. law firm representing investors in securities class actions. Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering $1.6 billion for investors last year, more than double the amount recovered by any other securities plaintiffs’ firm. Please visit https://www.rgrdlaw.com/firm.html for more information.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210818005108/en/
CONTACT: Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: LEGAL PROFESSIONAL SERVICES
SOURCE: Robbins Geller Rudman & Dowd LLP
Copyright Business Wire 2021.
PUB: 08/18/2021 10:53 PM/DISC: 08/18/2021 10:53 PM